Anti-glycoprotein-210 antibodies
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Autoantibody(s) | |
|---|---|
| Anti-glycoprotein-210 | |
| Autoantigen Isoform | Nucleoporin 210kDa |
| Autoantigen gene | NUP210 |
| Affected organ(s) | Bile Duct |
| AssociatedDisease(s) | Primary biliary cirrhosis |
| HLA associations | DR2 (weak) |
Anti-glycoprotein-210 antibodies (AGPA, anti-gp210, anti-nup210, anti-np210) are directed at gp210[1] and are found within primary biliary cirrhosis (PBC) patients in high frequency. AGPA recognize the cytoplasmic oriented carboxyl terminus (tail) of the protein.[1] While AGPA is found as a prognostic marker in only a minority of PBC patients those that did had higher mortality and predicts a poor outcome.[1] In addition patients that responded to ursodeoxycholic acid (UDCA) therapy and, therefore, had AGPA reductions failed to develop end-stage liver disease relative to untreated cohort with anti-gp210 Ab.[1] PBC patients with potentially destructive
AGPA have increased expression of Nup210 in the bile duct, a potential immune tolerance-escaping factor.[1]
Anti-mitochondrial, anti-centromere[1] and anti-p62 antibodies are also found in (PBC). While patients with AGPA progress toward end-stage liver failure, patients with anti-centromere antibodies often progress toward portal hypertension, further indicating a specific role of the AGPA in PBC.
Notes
gp210 is commonly used in the literature. The gene, NUP210, encodes the Nuclear pore (Nuclear porin) glycoprotein-210 that is a major component of the human nuclear pore complex.
